Page last updated: 2024-08-22

camptothecin and Blood Diseases

camptothecin has been researched along with Blood Diseases in 50 studies

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (12.00)18.2507
2000's30 (60.00)29.6817
2010's14 (28.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T1
Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP1
Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J1
Huang, J; Lyu, X; Tao, Y; Tian, Y; Wang, W; Wu, D; Yang, L1
Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L1
Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS1
Assadourian, S; Brooks, M; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Giammarile, F; Michon, J; Morland, B; Pichon, F; Rubie, H; Schell, M; Stockdale, E; Vassal, G1
Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R1
Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N1
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC1
Jang, SY; Jung, YW; Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, DW; Nam, EJ1
Boehm, KA; Cartwright, T; McCollum, D1
Bosnjakovic, PM; Howard, J; Martin, RC; Padr, R; Robbins, K; Tatum, C; Tomalty, D1
Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S1
Bedenne, L; Bonnetain, F; Brixi-Benmansour, H; Cadiot, G; Hentic, O; Jouve, JL; Landi, B; Mitry, E1
Chu, Z; Huang, M; Lu, G; Mao, Y; Yuan, B; Zhang, X; Zou, Y1
Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA1
Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J1
Beijnen, JH; Breda, M; Fraier, D; Grazia Porro, M; Jansen, S; Lieverst, J; Pellizzoni, C; Rosing, H; Schellens, JH; Schoemaker, NE; Spinelli, R; Swart, M; ten Bokkel Huinink, WW; van Kesteren, C1
Fukuda, M; Ichiki, M; Kawabata, S; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Nakatomi, K; Narasaki, F; Oka, M; Rikimaru, T; Soda, H; Takatani, H; Tsurutani, J1
Aoki, F; Kaminishi, M; Mafune, K; Shimizu, N; Shimoyama, S; Tatsutomi, Y1
Ballesteros, P; Bohn, U; Cassinello, J; Dorta, J; Fernández, JL; Huidobro, G; Jorge, M; López, R; López-Alvarez, P; Martínez-Guisado, A; Pérez-Carrión, R; Sevilla, I; Valladares, M1
de Jonge, MJ; Devlin, M; Gelderblom, H; Obach, R; Pentheroudakis, G; Principe, P; Pruñonosa, J; Salazar, R; Seguy, F; Twelves, C; van Hooije, C; Verweij, J1
Blay, P; Buesa, JM; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Sánchez, R; Uña, E; Vieitez, JM; Villanueva, N1
Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS1
Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J1
Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C1
Acusa, A; Antón, I; Batiste-Alentorn, E; Campos, JM; Guasch, I; Losa, F; Manzano, H; Saigi, E; Salut, A; Vélez de Mendizabal, E1
Briasoulis, E; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Rammou, D; Timotheadou, H1
Blankenburg, T; Bork, I; Juergens, S; Nagel, S; Schaedlich, S; Schuette, W; Wollschlaeger, B1
di Gennaro, G; Schioppa, O; Simonelli, C; Tirelli, U; Vaccher, E1
Bauer, S; Blay, JY; Christensen, TB; Daugaard, S; Hartmann, JT; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; Schöffski, P; Van Glabbeke, M1
Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S1
Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Yoon, SJ1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH1
Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT1
Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH1
Kim, HJ; Kim, JH; Kim, SG; Kim, SH; Kwon, HC; Lee, S; Oh, SY1
Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E1
Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH1
Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC1
Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N1
Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Raderer, M; Scheithauer, W; Valencak, J; Weinländer, G1
Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J1
Dallaire, BK; de Jonge, MJ; Loos, WJ; Sparreboom, A; Verweij, J1
Fujita, A; Sekine, K; Tagaki, S; Takabatake, H1
Allegra, CJ; Arbuck, SG; Band, RA; Berger, NA; Berger, SJ; Chen, AP; Cottrell, J; Flemming, D; Gosky, DM; Grem, JL; Guemei, A; Hamilton, JM; Harold, N; Hehman, H; Hirota, H; Ismail, AS; Llorens, V; Monahan, BP; Morrison, G; Quinn, M; Shapiro, JD; Takimoto, CH; Wright, J1
Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A1
Fukuoka, M; Negoro, S; Nitta, T; Takeda, K; Takifuji, N; Terakawa, K; Yoshimura, N1
Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Niitani, H; Taguchi, T; Takada, M; Takifuji, N1

Reviews

4 review(s) available for camptothecin and Blood Diseases

ArticleYear
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A

2010
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome

2010
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis

2008
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
    Clinical lung cancer, 2007, Volume: 8, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting

2007

Trials

40 trial(s) available for camptothecin and Blood Diseases

ArticleYear
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
    International journal of clinical oncology, 2019, Volume: 24, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Retrospective Studies; Treatment Outcome

2019
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss

2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome

2015
Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Drug Dosage Calculations; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Glucuronosyltransferase; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Stomach Neoplasms; Tomography, X-Ray Computed

2016
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome

2008
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:16

    Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infant; Injections, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Prospective Studies; Thoracic Neoplasms; Treatment Outcome; Young Adult

2008
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms

2010
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome

2010
Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.
    Cardiovascular and interventional radiology, 2010, Volume: 33, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Colorectal Neoplasms; Confidence Intervals; Digestive System Diseases; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hypertension; Irinotecan; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Registries; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome

2010
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Treatment Outcome

2011
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting

2002
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel

2002
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
    British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6

    Topics: Acrylamides; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Urinary Bladder Diseases

2002
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:15

    Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis

2002
Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome

2003
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-15, Volume: 9, Issue:11

    Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms

2003
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoplasms; Polymorphism, Genetic; Tablets; Tegafur; Treatment Outcome; Uracil

2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    BMC cancer, 2004, Jul-16, Volume: 4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate

2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    BMC cancer, 2004, Jul-20, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome

2004
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
    Anti-cancer drugs, 2004, Volume: 15, Issue:9

    Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prognosis; Survival Rate

2004
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
    Anti-cancer drugs, 2004, Volume: 15, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Greece; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Patient Selection; Taxoids; Time Factors; Treatment Outcome; Withholding Treatment

2004
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
    Clinical lung cancer, 2005, Volume: 7, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome

2005
Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma.
    AIDS (London, England), 2005, Nov-04, Volume: 19, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Camptothecin; Hematologic Diseases; HIV Infections; Humans; Irinotecan; Male; Middle Aged; Sarcoma, Kaposi; Treatment Outcome

2005
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leiomyosarcoma; Male; Middle Aged; Prospective Studies; Sarcoma, Synovial; Treatment Outcome

2007
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis

2008
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate

2008
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Floxuridine; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate

2007
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Nausea; Salvage Therapy; Stomach Neoplasms; Stomatitis; Survival Rate; Treatment Outcome

2007
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Disease-Free Survival; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Myocardial Ischemia; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Adjuvant; Survival Analysis

2008
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Disease Progression; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis; Taxoids

2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting

2008
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
    British journal of cancer, 1997, Volume: 76, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

1997
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin

1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome

1999
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
    Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Saliva

1999
Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
    Oncology, 1999, Volume: 56, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome

1999
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Vomiting

2000
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome

2000
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged

2001
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
    Journal of the National Cancer Institute, 1991, Aug-21, Volume: 83, Issue:16

    Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged

1991

Other Studies

7 other study(ies) available for camptothecin and Blood Diseases

ArticleYear
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
    British journal of cancer, 2016, 09-06, Volume: 115, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome

2016
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Retrospective Studies; Stomach Neoplasms; Taxoids; Young Adult

2010
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Hematologic Diseases; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Risk Factors; Tegafur

2010
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats.
    Regulatory toxicology and pharmacology : RTP, 2012, Volume: 64, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Camptothecin; Female; Hematologic Diseases; Humans; Irinotecan; Kidney; Liver; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyenes; Rats; Rats, Sprague-Dawley; TNF-Related Apoptosis-Inducing Ligand

2012
Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
    International journal of clinical oncology, 2003, Volume: 8, Issue:1

    Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome

2003
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.
    Investigational new drugs, 2003, Volume: 21, Issue:4

    Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Irinotecan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Taxoids

2003
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan

2008